Howe & Rusling Inc. Reduces Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Howe & Rusling Inc. decreased its position in Eli Lilly and Company (NYSE:LLY) by 10.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 631 shares of the company’s stock after selling 71 shares during the period. Howe & Rusling Inc.’s holdings in Eli Lilly and Company were worth $368,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Lipe & Dalton purchased a new position in Eli Lilly and Company in the fourth quarter valued at approximately $26,000. Thompson Investment Management Inc. purchased a new stake in shares of Eli Lilly and Company during the third quarter worth $27,000. Legacy Financial Group LLC purchased a new stake in shares of Eli Lilly and Company during the third quarter worth $35,000. Optiver Holding B.V. purchased a new stake in shares of Eli Lilly and Company during the third quarter worth $36,000. Finally, Family CFO Inc purchased a new stake in shares of Eli Lilly and Company during the third quarter worth $40,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the topic of several recent research reports. Citigroup increased their target price on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. The Goldman Sachs Group increased their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. Bank of America increased their target price on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Finally, Morgan Stanley increased their price objective on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research report on Friday, February 16th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $757.95.

Eli Lilly and Company Stock Up 0.4 %

LLY opened at $780.00 on Thursday. The stock has a market cap of $741.12 billion, a PE ratio of 114.40, a P/E/G ratio of 1.58 and a beta of 0.37. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a 52 week low of $414.31 and a 52 week high of $800.78. The business’s fifty day simple moving average is $762.03 and its 200 day simple moving average is $669.96.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, April 30th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 59.28% and a net margin of 17.08%. The firm had revenue of $8.77 billion for the quarter, compared to analysts’ expectations of $8.94 billion. During the same period last year, the firm earned $1.62 earnings per share. The company’s revenue for the quarter was up 26.0% compared to the same quarter last year. As a group, research analysts expect that Eli Lilly and Company will post 13.5 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.